摘要
目的探讨沐舒坦佐治慢性肺源性心脏病急性加重期的临床疗效。方法132例患者随机分为治疗组与对照组,对照组采用常规治疗,治疗组在常规治疗基础上加用沐舒坦治疗,7～10天后对比两组的治疗效果。结果治疗组与对照组的有效率分别为83.33%、65.15%,入住RICU的机率分别为7.58%、22.73%,两者比较差异有显著性。结论沐舒坦能提高慢性肺源性心脏病急性加重期的疗效,改善预后。
Objective To evaluate the clinic effect of using Mucosolvan on the treatment of acute aggravation period of Chronic Pulmonary Heart Disease. Methods Randomly divide 132 cases of Chronic Pulmonary Heart Disease into two groups： control group（66 cases） and treatment group（66 cases）. To Evaluate their clinic effect after 7～ 10d therapy. Results the Clinic effect of treatment group is superior to control group, the difference is significant（p〈0.05）. Conclusions Mucosolvan can improve the clinic effect of acute aggravation period of Chronic Pulmonary Heart Disease.
出处
《海南医学》
CAS
2005年第10期3-3,7,共2页
Hainan Medical Journal
关键词
沐舒坦
慢性肺源性心脏病
急性加重期
Mucosolvan
acute aggravation period ,Chronic Pulmonary Heart Disease
